Celcuity Inc.
No SEC Form 4 filings for $CELC in the last 30 days.
See all $CELC insider activity →Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.
Celcuity Inc (NASDAQ:CELC) reported a Q2 loss of $1.07 per share, narrower than the $1.17 consensus estimate, and down from a year-ago loss of 93 cents. Pre-market, shares rose 0.7% to $87.17. After the earnings release, Needham and Stifel kept Buy ratings but cut price targets to $140 and $150.
Analyst estimates for Celcuity Inc. show the average 12-month price target was cut from $163.55 to $160.64, with a range of $140 to $178 per share, according to 11 analysts. Based on the Aug. 13 closing price, the target suggests about 85% upside. The consensus rating remains “Buy” with 12 Buys, 0 Holds, and 0 Sells.
Over the past 7 days, alphai's AI scored 4 news stories mentioning CELC (Celcuity Inc.). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent CELC coverage spans earnings, financial news and regulation.
New clinical discontinuation read-through for REVTORPYK, plus launch and manufacturing shipment timing, can shift near-term risk perception and biotech trading sentiment.
Earnings beat but sell-side price targets were lowered, implying valuation or forward outlook concerns despite the EPS beat.
The article signals a modest downward shift in Street expectations, but consensus remains Buy with a large implied upside versus the Aug. 13 close.
Regulatory approval plus commercialization timing and updated Phase 3 efficacy/safety details increase near-term fundamental visibility for CELC.
NCCN Category 1 recommendation can improve prescribing confidence and payer/market access expectations for Celcuity’s Revtorpyk regimen.
alphai scores every news story that mentions CELC with an AI model for sentiment and relevance, and aggregates insider trades from Celcuity Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.
5 min readCelcuity Inc (NASDAQ:CELC) reported a Q2 loss of $1.07 per share, narrower than the $1.17 consensus estimate, and down from a year-ago loss of 93 cents. Pre-market, shares rose 0.7% to $87.17. After the earnings release, Needham and Stifel kept Buy ratings but cut price targets to $140 and $150.
2 min readAnalyst estimates for Celcuity Inc. show the average 12-month price target was cut from $163.55 to $160.64, with a range of $140 to $178 per share, according to 11 analysts. Based on the Aug. 13 closing price, the target suggests about 85% upside. The consensus rating remains “Buy” with 12 Buys, 0 Holds, and 0 Sells.
1 min readCelcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta
7 min readCelcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.
4 min readCelcuity Inc. (NASDAQ: CELC) said it received FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) but expects a commercial launch in late Q3 2026, later than some analyst expectations. The stock fell more than 17% after the announcement. Kessler Topaz Meltzer & Check is investigating potential securities law violations.
4 min readCelcuity’s REVTORPYK (gedatolisib) was approved by the US FDA in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA wild-type, in combination with fulvestrant, with or without palbociclib, after progression on endocrine therapy. VIKTORIA-1 (n=392) showed arm A median PFS 9.3 vs 2.0 months for fulvestrant alone, ORR 32% vs 1%. Commercial launch planned for late Q3 2026.
6 min readPomerantz LLP says it is investigating Celcuity Inc. for possible securities fraud after Celcuity announced a delayed commercial launch for its FDA-approved breast cancer drug Revtorpyk. The launch was pushed to late Q3 2026, later than analysts expected, and Celcuity shares fell 17.6% on July 15, 2026. The probe concerns whether the delay involved unlawful practices.
3 min readCelcuity (Nasdaq: CELC) said the FDA approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one endocrine therapy line. The VIKTORIA-1 data showed a progression-free survival benefit, with higher stomatitis, rash and metabolic side effects. The stock was reported down 17.4%.
6 min readHealthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.
7 min read
